T-Mobile has committed to offering the same or better rate plans as those offered as of today’s date for three years following the merger, reported Reuters. If the Federal Communications Commission (FCC) approves the telecom company’s US$26 billion merger with competitor Sprint, T-Mobile will put price increases on hold for three years, T-Mobile CEO John Legere wrote in note sent this week to FCC Chairman Ajit Pai.
“While we are combining our networks over the next three years, T-Mobile today is submitting to the commission a commitment that I stand behind — a commitment that New T-Mobile will make available the same or better rate plans for our services as those offered today by T-Mobile or Sprint,” Legere wrote in the letter.
Some critics have opposed the deal, announced in April, saying the elimination of one of the four largest wireless providers—Sprint is the No. 4, behind Verizon, AT&T, and T-Mobile—will lead to higher prices and harm consumers.
The pledge comes a week before two committees in the House of Representatives—Energy and Commerce and Judiciary—hold a joint hearing to discuss the transaction. The hearing is set for February 13, and both Legere and Sprint Chairman Marcelo Claure have agreed to testify.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Microsoft Nears EU Antitrust Resolution Over Teams Bundling, Sources Say
May 14, 2025 by
CPI
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas